New law to stabilise SHI fund finances – Changes to AMNOG are now finalized
On Friday, 21 Oct 2022, the German House of Representatives has now finalized the law on the financial stabilization of statutory health
Tag: AMNOG process
Another cancer drug by Janssen unlikely to be available in Germany
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Federal Cabinet has agreed new law to stabilise SHI finances
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),
AOK raises further critique on draft law to stabilise SHI finances
Recently, I wrote about the planned reforms that the German Health Minister, Karl Lauterbach, wants to introduce with the act to stabilise
German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
What’s important to know about real-world evidence data collection in Germany?
In this post, I’ll summarise the key points on the real-world evidence data collection in Germany, that the G-BA can request since
The German Health Minister reveals his plans for the next months
Welcome to another post on possible changes and the plans of the German Health Minister for the healthcare system in the next
How will German early benefit assessments change in the future?
Welcome to the last post in the HTA series, focusing on the changes to HTA and early benefit assessments in Germany in
How does the G-BA pick the appropriate comparator?
Welcome! In this post, I am going through the steps on how the G-BA chooses the appropriate comparative therapy (ACT). I conclude
Which endpoints are important to the G-BA and IQWiG?
Welcome, this week’s post on the G-BA’s views on endpoints is the second article in the benefit assessments series. You’ll learn about: